Forskning ved Københavns Universitet - Københavns Universitet

Forside

Adverse effect of tocilizumab treatment on split thickness skin graft: a case report

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Tocilizumab is a biological immunosuppressive drug used in the treatment of psoriasis arthritis. It works by blocking the interleukin 6 receptor and therefor blocking the immune response caused by IL-6 which plays an important role in arthritis. Tocilizumab is commonly used in RA patients who either have experienced insufficient effect of other treatment options or who have had unacceptable side effects from previous treatment. With this case report, we would like to raise awareness of a potentially previously unheard of adverse effect of tocilizumab treatment on split thickness skin graft (STSG). We present a case of a 61-year-old man, treated with tocilizumab for severe poly-articular, erosive psoriasis arthritis. He was diagnosed with BCC on the scalp and underwent excision followed by STSG with no complications. The patient experienced graft loss after commencing tocilizumab treatment days to weeks post grafting on numerous occasions. We find this possible adverse effect of tocilizumab on skin grafts to be of great importance to report as it is not previously mentioned in any literature. We hope that this case report will increase the awareness of this possible adverse effect on STSG in patients treated with tocilizumab (TCZ). As the patient is dependent on arthritis symptoms to be well controlled, it is of great importance to both medical and surgical teams responsible for treatment to be able to collaborate to plan best treatment, timing, and strategy.Level of Evidence: Level V, risk / prognostic study Level of Evidence: Level V, risk / prognostic study.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Plastic Surgery
Vol/bind42
Udgave nummer1
Sider (fra-til)101-104
ISSN0930-343X
DOI
StatusUdgivet - 2019

ID: 241578623